12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Subcutaneous Cinryze: Phase II resumed

Halozyme and partner ViroPharma said FDA lifted a clinical hold on a Phase II trial of subcutaneous Cinryze in combination with Halozyme's recombinant human PH20 hyaluronidase ( rHuPH20) for HAE. The partners said they can restart the Phase II trial after they submit a revised protocol to allow for increased monitoring of rHuPH20 antibody levels. FDA also requested...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >